rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Citius Pharmaceuticals, Inc.

CTXR · Nasdaq

Health CareBiotechnologyNot moving yet

CTXR stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 46 weeks. It is 33.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 46
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
42 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders42+7 on the quarter
New · exited13 · 6
Reported value$810K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026215,537$130K-30,621−12.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026197,364$119K+29,626+17.7%
Miller Financial Services LLCadded · filed 29 Jul 2026130,000$79K+116,000+828.6%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026124,910$76K+124,910
JANE STREET GROUP, LLCadded · filed 14 Aug 2026122,837$74K+100,314+445.4%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202677,755$47K00.0%
BlackRock, Inc.reduced · filed 7 Aug 202669,850$42K-10.0%
NORTHERN TRUST CORPadded · filed 13 Aug 202662,742$38K+18,768+42.7%
XTX Topco Ltdadded · filed 14 Aug 202659,199$36K+37,904+178.0%
Asset Advisory Group, Inc.unchanged · filed 9 Jul 202659,011$36K00.0%
31 Dec 2024 – 30 Jun 2026
273441Dec 24Jun 25Sep 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Leonard L. Mazur Company insiderChief Executive Officer · last 8 Aug 20258 · 0
Myron Z. Holubiak Company insiderVice Chairman · last 8 Aug 20254 · 0
Carol Webb Company insiderDirector · last 7 Nov 20240 · 0
Dennis M. McGrath Company insiderDirector · last 7 Nov 20240 · 0
Eugene Myron Holuka Company insiderDirector · last 7 Nov 20240 · 0
Jaime Bartushak Company insiderChief Financial Officer · last 7 Nov 20240 · 0
Myron Czuczman Company insiderChief Medical Officer · last 7 Nov 20240 · 0
Robert Joseph Smith Company insiderDirector · last 7 Nov 20240 · 0
Suren G. Dutia Company insiderDirector · last 7 Nov 20240 · 0
Howard Safir Company insiderDirector · last 4 Oct 20220 · 0
William Kane Company insiderDirector · last 4 Oct 20220 · 0

Same industry

MRNA ModernaLeading+167%
IOVA Iovance BiotherapeuticsLeading+141%
ABCL AbCellera BiologicsLeading+57%
ENTX Entera BioLeading+52%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+47%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 30 Sep 2025-44.8%
Share count trendFY 2025 · to 17 Dec 202514.9%
Cash and equivalentsFY 2025 · to 30 Sep 2025$4.3M

Analyst forecasts

No analyst forecasts yet.